- Home
- XOMAP vs PEV Comparison
XOMAP vs PEV Comparison
Compare XOMAP & PEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- PEV
- Stock Information
- Founded
- XOMAP N/A
- PEV 2002
- Country
- XOMAP United States
- PEV United States
- Employees
- XOMAP 13
- PEV N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- PEV Auto Manufacturing
- Sector
- XOMAP Health Care
- PEV Consumer Discretionary
- Exchange
- XOMAP Nasdaq
- PEV Nasdaq
- Market Cap
- XOMAP N/A
- PEV N/A
- IPO Year
- XOMAP N/A
- PEV 2022
- Fundamental
- Price
- XOMAP $25.95
- PEV N/A
- Analyst Decision
- XOMAP
- PEV
- Analyst Count
- XOMAP 0
- PEV 0
- Target Price
- XOMAP N/A
- PEV N/A
- AVG Volume (30 Days)
- XOMAP N/A
- PEV 2.8M
- Earning Date
- XOMAP N/A
- PEV 05-22-2025
- Dividend Yield
- XOMAP N/A
- PEV N/A
- EPS Growth
- XOMAP N/A
- PEV N/A
- EPS
- XOMAP N/A
- PEV 0.06
- Revenue
- XOMAP N/A
- PEV $26,119,000.00
- Revenue This Year
- XOMAP N/A
- PEV N/A
- Revenue Next Year
- XOMAP N/A
- PEV N/A
- P/E Ratio
- XOMAP N/A
- PEV $4.91
- Revenue Growth
- XOMAP N/A
- PEV 424.69
- 52 Week Low
- XOMAP N/A
- PEV $0.20
- 52 Week High
- XOMAP N/A
- PEV $1.39
- Technical
- Relative Strength Index (RSI)
- XOMAP 52.85
- PEV 30.85
- Support Level
- XOMAP $24.96
- PEV $0.06
- Resistance Level
- XOMAP $26.10
- PEV $0.30
- Average True Range (ATR)
- XOMAP 0.38
- PEV 0.07
- MACD
- XOMAP 0.03
- PEV -0.03
- Stochastic Oscillator
- XOMAP 76.74
- PEV 14.42
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.